In a report issued on May 21, David Buck from B.Riley FBR assigned a Buy rating to Endo International (NASDAQ: ENDP), with a price target of $10. The company’s shares closed yesterday at $5.95, close to its 52-week low of $5.27.
Buck observed:
“We continue to recommend Buy-rated ENDP shares with a $10 price target as a stabilization and turnaround story. We have updated our model with no material changes following review of our model and our adjusted EPS of $2.45 (unchanged) stays at high-end of Endo’s 2018 guidance of $2.15-$2.55 in adjusted EPS guidance while our 2018E adjusted EBITDA of $1.29M stays at higher-end of 2018 guidance of $1.2-$1.3B. At an investor conference, Endo’s CEO Paul Campanelli characterized heavy lifting on products, plants and personnel as largely behind it and there is cautious optimism on stabilization in generic pricing. Endo’s 2018 growth drivers include U.S. 2017 sales) and US specialty brands, a subset of total U.S. branded drugs at ~13% of 2017 sales.”
According to TipRanks.com, Buck is a 4-star analyst with an average return of 16.3% and a 75.0% success rate. Buck covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics Inc, Spectrum Pharmaceuticals, and Supernus Pharmaceuticals.
Endo International has an analyst consensus of Hold, with a price target consensus of $8.08.
See today’s analyst top recommended stocks >>
Based on Endo International’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $505 million. In comparison, last year the company had a GAAP net loss of $174 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The company operates through the following segments: U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals and International Pharmaceuticals.
Read More on ENDP:
